ORIGINAL RESEARCH
Accepted on 28 Oct 2025
CldU Sensitizes BRCA2 Reverse-Mutated Cells to PARP Inhibitors
- 165 views
- Frontiers in Oncology
- Cancer Molecular Targets and Therapeutics
- Research Topics
- Innovative Drug Combinations for Enhanced Solid Tumor Treatment Efficacy
Innovative Drug Combinations for Enhanced Solid Tumor Treatment Efficacy
3,850
Total downloads
21k
Total views and downloads
Articles
CASE REPORT
Published on 22 Oct 2025
Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
doi 10.3389/fonc.2025.1587752
- 684 views
CASE REPORT
Published on 20 Oct 2025
HER2 inhibitor-based combination therapy for recurrent and metastatic salivary duct carcinoma in an elderly patient: a case report and literature review
doi 10.3389/fonc.2025.1590497
- 779 views
CASE REPORT
Published on 17 Sep 2025
Etoposide and cisplatin in combination with anlotinib for lung NUT carcinoma: a case report
doi 10.3389/fonc.2025.1632133
- 900 views
ORIGINAL RESEARCH
Published on 10 Sep 2025
KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC
doi 10.3389/fonc.2025.1654491
- 1,565 views
ORIGINAL RESEARCH
Published on 08 Sep 2025
Outstanding treatment success of pembrolizumab and bevacizumab combination therapy in first-line treatment of cervical sarcomatoid carcinoma: a rare case report
doi 10.3389/fonc.2025.1586531
- 1,101 views
ORIGINAL RESEARCH
Published on 01 Sep 2025
Diaryl pyrimidine guanidine suppresses hepatocellular carcinoma cell stemness by targeting β-catenin signaling
doi 10.3389/fonc.2025.1641979
- 926 views
ORIGINAL RESEARCH
Published on 19 Aug 2025
Combined treatment with CDK4/6, CDK2, and CXCR1/2 inhibitors effectively halts the growth of BRAF wild-type melanoma tumors
doi 10.3389/fonc.2025.1609735
- 2,248 views
REVIEW
Published on 22 Jul 2025
SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance
doi 10.3389/fonc.2025.1582738
- 2,159 views
ORIGINAL RESEARCH
Published on 04 Jun 2025
Aumolertinib plus bevacizumab for untreated advanced NSCLC with EGFR sensitive mutation
doi 10.3389/fonc.2025.1595812
- 1,648 views
ORIGINAL RESEARCH
Published on 16 May 2025
A trispecific antibody targeting EGFR/cMET/VEGF-A demonstrates multiple mechanisms of action to inhibit wild-type and mutant NSCLC animal models
doi 10.3389/fonc.2025.1533059
- 3,280 views
- 1 citation
CASE REPORT
Published on 26 Feb 2025
Efficacy of anlotinib and chemotherapy combination as neoadjuvant therapy in the treatment of pulmonary artery intimal sarcoma: a case report
doi 10.3389/fonc.2025.1507281
- 1,061 views
